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Abstract
Background: The most important receptor for nitic oxide is the soluble guanylate cyclase (sGC),
a heme containing heterodimer. Recently, a pyrazolopyridine derivative BAY 41-2272, structurally
related to YC-1, was identified stimulating soluble guanylate cyclase in an NO-independent manner,
which results in vasodilatation and antiplatelet activity. The study described here addresses the
identification of the NO-independent site on soluble guanylate cyclase.
Results: We developed a photoaffinity label (3H-meta-PAL) for the direct and NO-independent
soluble guanylate cyclase (sGC) stimulator BAY 41-2272 by introducing an azido-group into the
tritium labeled compound. The synthesized photoaffinitylabel directly stimulates the purified sGC
and shows in combination with NO a synergistic effect on sGC activity. Irradiation with UV light
of 3H-meta-PAL together with the highly purified sGC leads to a covalent binding to the α 1-subunit
of the enzyme. This binding is blocked by unlabeled meta-PAL, YC-1 and BAY 41-2272. For further
identification of the NO-independent regulatory site the 3H-meta-PAL labeled sGC was
fragmented by CNBr digest. The 3H-meta-PAL binds to a CNBr fragment, consisting of the amino
acids 236–290 of the α 1-subunit. Determination of radioactivity of the single PTH-cycles from the
sequencing of this CNBr fragment detected the cysteines 238 and 243 as binding residues of the
3H-meta-PAL.
Conclusions: Our data demonstrate that the region surrounding the cysteines 238 and 243 in the
α 1-subunit of the sGC could play an important role in regulation of sGC activity and could be the
target of this new type of sGC stimulators.
Background
Guanylate cyclases (GTP pyrophosphate-lyase [cyclizing];
EC 4.6.1.2) catalyze the biosynthesis of guanosine 3',5'-
cyclic monophosphate (cGMP) from GTP. While the
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membrane bound forms are monomers and stimulated
by the natriuretic peptides, the soluble guanylate cyclases
(sGC) exist as heterodimers consisting of an α 1- and a β 1-
subunit and containing heme as a prosthetic group [1].
Besides this major species of sGC there exist also reports
of homodimeric forms of this enzyme [2,3]. By formation
of cGMP as a second messenger, sGC plays an important
role in smooth muscle cell relaxation [4], inhibition of
platelet aggregation, retinal signal transduction [5] and
synaptic transmission [6]. The enzyme is strongly activat-
ed by NO [7], by the new direct and NO-independent
stimulator YC-1 [8–11], and to a lesser extend by CO [12–
14,11]. Thus in several studies YC-1 was shown to be an
antithrombotic agent by elevation of cGMP, VASP phos-
phorylation and inhibiting platelet aggregation [8,13,15–
18]. Furthermore YC-1 was shown to relax precontracted
aortic rings [9], even if they were made tolerant with glyc-
eryl trinitrite [19] and to induce a dose-dependent de-
crease in systolic blood pressure [19]. Interestingly, in
addition to the direct activation of the purified sGC by YC-
1, an overadditive effect was observed by the combina-
tions of YC-1 and NO or CO [9–11,18,20]. It was shown
that YC-1 is a heme-dependent but NO-independent
stimulator of sGC [11,13]. In contrast to NO and CO
which directly interact with the heme group of the en-
zyme, YC-1 did not change the spectral characteristics of
the heme moiety of sGC [11]. Therefore it is believed that
YC-1 did not interact directly with the heme region of the
sGC. Because YC-1 sensitises the enzyme towards their en-
dogenous ligands NO and CO, it is proposed that YC-1
binds to an allosteric site on sGC and thereby reduces the
ligand dissociation rates from the heme group
[10,11,20,21].
Recently, we described the pharmacological profile of a
new sGC stimulator – BAY 41-2272 with similar charac-
teristics like YC-1, however, with a distinctly higher poten-
cy and no PDE inhibitory activity [22]. Using BAY 41-
2272 as lead structure of this new pharmacological princi-
ple, we synthesized the first photoaffinity label derived
from the BAY 41-2272 chemical core structure, character-
ized it on the purified enzyme, labeled the highly purified
sGC, and identified the binding amino acids of this new
type of sGC stimulators.
Results
We developed the first photoaffinity label for direct and
NO-independent sGC stimulators. Coming from YC-1
and BAY 41-2272 as lead structures of direct and NO-in-
dependent sGC stimulators we synthesized the ortho-
(BAY 50-6038), meta- (BAY 51-9491) and para-PAL (BAY
50-8364) compounds (Fig. 1) and tested their influence
on sGC activity. The meta- and para-PAL showed on the
one hand a direct sGC stimulation comparable to YC-1
and on the other hand in combination with NO distinct
synergistic effects on sGC activity. The ortho-PAL showed
the lowest sGC stimulation and in combination with NO
no synergistic effect on sGC activity (Tab. 1). Both under
reducing conditions and in the absence of DTT, in the sGC
assay a similar sGC activating profile of the three PALs is
given (Tab. 1). Because of the more dominant stimulation
of sGC by the single compound both in the presence and
absence of DTT the meta-PAL compound was chosen as
photoaffinitylabel for the following studies (Tab. 1).
Similar to YC-1 and BAY 41-2272, meta-PAL (BAY 51-
9491) concentration-dependently stimulates purified
sGC and shows in combination with NO a potentiation of
sGC activity, while in combination with YC-1, only addi-
tive effects could be detected. sGC stimulation by meta-
PAL could be nearly completely blocked by ODQ and is
dependent of the presence of the prosthetic heme-moiety
of sGC (Fig. 3a). As YC-1, meta-PAL does not shift the po-
sition of the Soret band of sGC both under basal and NO
stimulated conditions (Fig. 3b).
To optimize the irradiation conditions for the following
photoaffinity studies, the NH- and CH-insertion qualities
of meta-PAL (BAY 51-9491) were studied in the presence
of different solution compounds by irradiation under 254
or 365 nm. As shown in Tab. 2, NH-insertion was more ef-
fective than CH-insertion under our conditions. UV 254
nm was chosen as irradiation source. In addition, the time
dependency of the photoactivation of the meta-PAL (BAY
51-9491) under UV 254 nm (40 Watt, distance of 3 cm)
was studied by thin layer chromatography (Rf of meta-
PAL = 0.7 and of photolysed meta-PAL = 0.5). The meta-
PAL was completely destroyed after irradiation in PAL
Figure 1
Synthesis of the ortho-, meta- and para-PAL compounds.
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buffer within 3 min. In the presence of glucose oxidase as
model protein, meta-PAL was completely destroyed after
an irradiation time of about 18 min (data not shown).
Therefore the irradiation time for the labeling studies was
chosen with 15 min under 254 nm (40 Watt) at a distance
of 3 cm.
For enzyme labeling, 3H-meta-PAL was synthesized as de-
scribed (Fig. 2). The binding of 3H-meta-PAL to highly pu-
rified sGC was studied both in the presence of different
concentrations of sGC as different concentrations of 3H-
meta-PAL, and also in the presence of unlabeled meta-
PAL (100 µM). As shown in Fig. 4, 3H-meta-PAL binds
concentration-dependently almost exclusively to the α 1-
subunit of the sGC after irradiation. The radiolabeling of
the β 1-subunit is only weakly visible in the autoradio-
gramm after reaction of sGC with 200 µCi 3H-meta-PAL.
In the presence of unlabeled meta-PAL (100 µM) the cov-
alent binding of the 3H-meta-PAL to the α 1-subunit is ob-
viously diminished in the presence of 20 or 2 µCi 3H-
meta-PAL.
In addition, we examined the effects of different sGC
modulators on binding of 3H-meta-PAL on purified sGC
(Fig. 5). Both unlabeled meta-PAL (100 µM and 10 µM),
YC-1 (100 µM), BAY 41-2272 [22] but also ODQ (100
µM) diminished concentration-dependently the binding of
3H-meta-PAL to the α 1-subunit. ODQ inhibit the binding
of the 3H-meta-PAL to the α 1-subunit, but in this case weak
unspecific labeling of the β 1-subunit and the α 1-subunit
was detected. 3H-meta-PAL processed with sGC without ir-
radiation showed no insertion of radioactivity (Fig. 5).
To identify the binding residues of the 3H-meta-PAL at the
α 1-subunit, sGC was labeled with 3H-meta-PAL and the
labeled protein was fragmented by CNBr cleavage. The re-
sulting protein fragments were separated by electrophore-
sis (10–20% SDS-PAGE), transferred to a PVDF
membrane, stained with Coomassie-blue and exposed to
Imaging-Plates (Fig. 6). The resulted autoradiogramm
shows five highly labeled protein fragments (CNBr I-V)
with molecular weights of 51.8 / 35.9 / 30.2 / 11.7 and 6.2
kDa (Fig. 6) which were identified and excised from the
Coomassie-blue stained Western blots. Sequencing of this
bands showed, that they contain different fragments of
both the α 1- as the β 1-subunit (Tab. 4). For better separa-
tion of peptides in the lower molecular weight range, the
same fragments were separated on a TRIS-Tricine-gel. In
this autoradiogramm we detected three highly labeled
protein fragments (CNBr VI-VIII) with molecular weights
of 14.7 / 11.7 and 6.2 kDa (Fig. 7). Before sequencing of
the different labeled sGC fragments, both intact subunits
Table 1: Stimulation of purified sGC in the presence and absence of DTT by the NO donor SNP. YC-1 and the ortho-. meta- and para-
PALs with Mg2+ as cofactor. Shown are the x-fold stimulations versus basal specific activity of SNP (1 µM). YC-1 (100 µM, 10 µM, 1 µM 
and 1 µM YC-1 in combination with 1µM SNP) and the different PALs (100 µM, 10 µM, 1 µM and 1 µM PAL in combination with 1 µM 
SNP). The data presented represent the mean ± SEM out of four independent experiments performed in duplicate.
Stimulation of purified sGC [fold increase vs. basal activity ± SEM] (basal specific activity [nmol/mg/min])
Stimulator Concentration + DTT -DTT
Basal 1.0 ± 0.1 (64 ± 8) 1.0 ± 0.2 (150.8 ± 33.4)
SNP 1 µM 82.3 ± 10.5 17.1 ± 2.2
100 µM 45.9 ± 7.7 44.4 ± 4.8
YC-1 10 µM4 . 5   ± 0.8 7.0 ± 1.7
1 µ M2 . 0  ± 0.4 1.5 ± 0.2
YC-1 + SNP 1 µM + 1 µM 98.4 ± 17.3 20.6 ± 3.6
100 µM 14.4 ± 1.6 21.4 ± 4.2
ortho-PAL 10 µM2 . 9   ± 1.5 3.1 ± 0.6
1 µ M2 . 1  ± 1.0 1.0 ± 0.1
ortho-PAL + SNP 1 µM + 1 µM 85.7 ± 11.4 15.8 ± 2.0
100 µM 54.7 ± 10.2 56.1 ± 0.1
meta-PAL 10 µM 21.3 ± 7.1 23.3 ± 4.1
1 µ M4 . 5  ± 1.0 4.9 ± 0.4
meta-PAL + SNP 1 µM + 1 µM1 8 5 . 6   ± 72.6 39.0 ± 5.6
100 µM 36.6 ± 3.5 30.2 ± 4.5
para-PAL 10 µM 15.3 ± 2.7 17.3 ± 1.9
1 µM3 . 5   ± 0.4 3.8 ± 0.3
para-PAL + SNP 1 µM + 1 µM2 2 9 . 1   ± 33.6 50.6 ±5.5BMC Pharmacology 2001, 1 http://www.biomedcentral.com/1471-2210/1/13
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of sGC were sequenced. We observed, that the first 20 cod-
ed amino acids of the α 1-subunit probably belong to the
presequence. The β 1-subunit corresponded to the pub-
lished sequence. Because of the selective labeling of the α 1-
subunit by the 3H-meta-PAL (Fig. 4 and 5), in Tab. 3 only
the theoretically CNBr fragments of the α 1-subunit (AS 20-
690) are aligned and signed after their position. It is known
that CNBr fragments show different migration properties in
SDS-PAGE related to the used molecular weightmarkers.
Therefore in the figures we used the calculated molecular
weights from sequencing to mark the labeled CNBr frag-
ments. The sequenced bands are marked in Fig. 6 and 7.
The results of the sequencing of the different fragments are
shown in Tab. 4. The overview of the determined α 1-se-
quences shows, that the 3H-meta-PAL specifically binds to
the CNBr VIII = CNBr-2 fragment of the α 1-subunit (Tab. 3
and 4) with the amino acids 236–290.
To more closely specify the binding site of the 3H-meta-
PAL, the single PTH-cycles from the sequencing of the
CNBr VIII fragment (Fig. 7 and Tab. 4) were collected,
lyophilised and the radioactivity of each fraction was
counted. Beside an unspecific "wash out", we determined
a distinct increase of radioactivity in the cycles 3 and 8 (>
10-fold over basal measured activity), which correspond
to the cysteines 238 and 243 (Fig. 8). Thereby 3H-meta-
PAL is bound to sGC after irradiation by the cysteines 238
and 243 of the α 1-subunit of the sGC (Fig. 9).
The putative target sequence of bovine sGC differs from
rat and human by the substitution of an arginine at posi-
tion 238 instead of cysteine. Therefore we investigated if
BAY 41-2272 is active against the bovine enzyme or in iso-
lated bovine vascular preparations. We prepared crude
sGC containing fraction from bovine lung by performing
the homogenization and ion-exchange steps of the meth-
od described earlier [11] with a specific basal activity of
0.15 nmol/mg/min. Using this preparation we examined
the characteristic of sGC stimulation by BAY 41-2272
alone and in the presence of high concentrations of DEA/
NO (Fig. 10). This study shows that BAY 41-2272 stimu-
lates directly the crude sGC-containing fraction from bo-
vine lung in a concentration dependent manner. In
combination, BAY 41-2272 and the NO donor DEA/NO
potentiates over a wide range of concentrations.
Figure 2
Synthesis of the 3H-meta-PAL.
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Figure 3
a) Stimulation of purified sGC by meta-PAL (0.3–100 µM) in
the absence and presence of DEA/NO (0.01, 0.1, and 1 µM),
YC-1 (30 µM) and ODQ (10 µM) and stimulation of heme-
depleted sGC by meta-PAL in the presence of DTT and Mg2+
as cofactor. The specific activity of sGC is expressed as x-
fold stimulation vs. basal activity (basal activity in the pres-
ence of Mg2+: 152 nmol/mg/min). The data presented repre-
sent means ± SEM, from 4 independent experiments
performed in duplicate. b) Heme spectra (OD: optic density)
of sGC under basal conditions and in the presence of the
NO donor DEA/NO and the meta-PAL. These data are rep-
resentative for three independent determinations.BMC Pharmacology 2001, 1 http://www.biomedcentral.com/1471-2210/1/13
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Table 2: CH- and NH-insertion of meta-PAL dissolved in the different solvents after quantitative LC/MS (results are given as % peak 
area of insertion product vs. total peak area).
NH-insertion CH-insertion
solvent
irradiation wavelength irradiation wavelength
254 nm 365 nm 254 nm 365 nm
diethylamine 87%, 91% 32%, 23% - -
dipropylamine 81%, 91% 21%, 18% - -
piperidine 61% 26% - -
toluene -- 4 9 % -
ethylbenzole - - 8% 2%
Table 3: Sequence of the marked CNBr fragments in figures 5 and 6. MW: molecular weight; AA: amino acid; the several amino acids 
are shown in the one-letter-code. Sequenced fragments of the α 1-subunit are signed as in Tab. 4, while CNBr fragments of the β 1-subunit 
are defined by the position of the determined AA in the subunit. The CNBr-2 fragment of the α 1-subunit, represented in all labeled 
bands,
CNBr-fragment α 1-subunit β 1-subunit Sequence from the N-terminus MW [kDa]
CNBr I CNBr -1 to 8 APGQVPTEPIEE... 51.8
CNBr II CNBr -1 to 4 APGQVPTEPIEE... 35.9
CNBr III CNBr -1 and 2 APGQVPTEPIEE... 30.2
CNBr IV CNBr 16 PRYCLFGNNVT... 11.2
CNBr 8 IYIVESSAILFLG... 12.5
CNBr -2 and 3 PPCFRSECTEF... 11.7
AA 505-619 EIAGQVQVDGE... 12.8
CNBr V CNBr -10 to 13 LNALYTRFDQQ... 6.5
CNBr 3 LDRDLAILQLG... 5.5
CNBr 2 PPCFRSECTEF... 6.2
AA 2-69 YGFVNHALELL... 7.7
AA 116-164 RAPSFRCTDAE... 5.5
AA 445-503 KIVNLLNDLYTR... 6.7
AA 538-592 PRYCLFGNTVN... 6.2
CNBr VI CNBr -2 to 6 PPCFRSECTEF... 14.7
CNBr 16 PRYCLFGNNVT... 11.2
AA 505-599 EIAGQVQVDGE... 10.4
CNBr VII CNBr -2 and 3 PPCFRSECTEF... 11.7
CNBr 8 IYIVESSAILFLG... 12.5
CNBr VIII CNBr 2 PPCFRSECTEF... 6.2
AA 445-480 KIVNLLNDLYTR... 4.3
AA 2-69 YGFVNHALELL... 7.7
AA 1-69 MYGFVNHALEL... 7.7BMC Pharmacology 2001, 1 http://www.biomedcentral.com/1471-2210/1/13
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Discussion
To identify the binding site of the new class of direct and
NO-independent sGC stimulators like YC-1 and the re-
cently described more potent compound BAY 41-2272
[22] we focus in this paper in addition to results, already
shown in Stasch et al. [22], on the detailed description of
the development of the first photoaffinity label by intro-
ducing a azidobenzoic acid at different positions (ortho-,
meta-, and para-PAL) into the BAY 41-2272 core structure.
As shown, all tested photoaffinitylabels stimulate the pu-
rified enzyme with similar characteristics as YC-1. sGC ac-
tivity increases from the ortho- to the para- to the meta-
PAL compound. In contrast to the ortho-PAL compound,
the meta- and para-PAL compounds show synergistic ef-
fects on sGC activity in combination with NO as described
for YC-1 and BAY 41-2272 [11,22] (Tab. 1). Therefore we
conclude from these structure-activity-relationship, that
the meta- and para-PALs in contrast to the ortho-PAL
match structurally with the new binding site of the sGC,
essentially regarding to the synergistic activation of sGC in
combination with its physiological stimulator NO and
thereby are useful tools in the identification of the new
binding site in sGC. In addition to Stasch et al.[22], we
demonstrate here different potential PALs, which differ in
their chemical structure and sGC stimulation characteris-
tics.
In forward to avoid an unproductive destruction of the
PAL during the labeling of the enzyme [34], stimulation
of sGC was not only tested under standardized conditions
[11] but also verified under modified conditions in the
absence of DTT. Even under this adapted conditions used
for the labeling of the enzyme, the PAL compounds stim-
ulate the purified enzyme with similar properties as YC-1
and BAY 41-2272. Under these conditions meta-PAL re-
veals to be the most potent compound with the same
characteristics on stimulation of sGC as YC-1 and BAY 41-
2272. As expected, meta-PAL shows no influence on the
position of the Soret band of sGC both under basal and
NO-stimulated conditions. Thereby meta-PAL belongs to
the new class of direct, NO-independent sGC stimulators,
which stimulate sGC by a heme-dependent mechanism
without a direct interaction with the heme-moiety
[11,22].
Moreover we characterize the insertion characteristics of
the meta-PAL. Concomitant with the literature, our meta-
PAL showed more potent NH- than CH-insertion quali-
ties and thereby is qualified for protein conjugation reac-
tions [35]. During irradiation with UV light (254 nm),
under our adapted conditions the meta-PAL completely
disintegrated within a time of maximal 18 min under re-
lease of nitrogen, detected by thin-layer-chromatography.
Beyond the fast reaction of azido compounds after irradi-
ation with UV, the quality of a photoaffinitylabel depends
on the stability of the compound and the radioactive label
and of the covalent binding properties of the compound
at or at least in the environment of the binding site [35].
Our compound is stable for several weeks stored at 70°C
(data not shown). Moreover, under reducing conditions,
where the sGC is distinctly stimulated by the meta-PAL,
and thereby the active conformation of the sGC should be
Table 4: Theoretical CNBr fragments of the α 1-subunit of the sGC. MW: molecular weight; AA: amino acid; the several amino acids are 
shown in the one-letter-code.
CNBr fragment MW [kDa] AA number AA position in the α 1 subunit Sequence from the N-terminus
CNBr-1 24 215 21–235 APGQVPTEPIEE...
CNBr -2 6.2 54 236–290 PPCFRSECTEFV...
CNBr -3 5.5 47 291–338 LDRDLAILQLG...
CNBr -4 0.2 2 339–340 TM
CNBr -5 0.3 3 341–343 LNM
CNBr -6 2.5 19 344–363 QFVIRVRRWDNL...
CNBr -7 0.6 6 364–369 DLKGQM
CNBr -8 12.5 111 370–481 IYIVESSAILFLG...
CNBr -9 2.4 22 482–504 LFSDIVGFTAICS...
CNBr -10 5.2 46 505–551 LNALYTRFDQQ...
CNBr -11 0.4 4 552–555 ALKM
CNBr -12 0.1 1 556 M
CNBr -13 0.8 7 557–563 ELSNEVM
CNBr -14 0.9 9 564–572 SPHGEPIKM
CNBr -15 1.8 17 573–590 RIGLHSGSVFAG...
CNBr -16 11.2 99 591–690 PRYCLFGNNVT...BMC Pharmacology 2001, 1 http://www.biomedcentral.com/1471-2210/1/13
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provided, the 3H-meta-PAL binds not only concentration-
dependently but also specifically to the α 1-subunit of the
sGC. Ideally, a classical receptor binding study would be
the best aproach to characterize the specific as well as un-
specific binding to sGC. However, due to the physiko-
chemical properties of the radioligand (e.g. low solubility,
lipophilic character, low specific activity) and the difficul-
ty that the receptor sGC is a soluble cytosolic enzyme, it
was not possible to separate free and bound radioligand.
For this reasons we were not able to establish this study.
Binding to the α 1-subunit of the enzyme was inert versus
all used analytical steps (e.g. TCA precipitation, acid CNBr
proteolyse, SDS-PAGE) and thereby underlines the quali-
ty of this new compound.
In a further study, the inhibition of this specifically bind-
ing of the 3H-meta-PAL to the α 1-subunit of the sGC by
several sGC modulators was examined. Thereby we could
show that the 3H-meta-PAL binds only after irradiation to
the α 1-subunit of the sGC, implicating that the 3H-meta-
PAL binds as a consequence of irradiation and not by an
unspecific interaction to the enzyme. After preincubation
with the purified sGC, the unlabeled meta-PAL(10 and
100 µM) as well as YC-1 (100 µM) or BAY 41-2272 [22]
inhibited the insertion of the 3H-meta-PAL in the α 1-sub-
unit, underlining the specificity of the binding. As shown
in Fig. 4, incubation with 200 µCi (125 µM) 3H-meta-PAL
in the presence of 100 µM unlabeled PAL showed only
slight competition due to the small access of unlabeled
compound. For this reason further competition studies
were performed with 12.5 µM 3H-meta-PAL (Fig. 5). In
addition, the specific inhibitor of sGC, ODQ [36], strong-
ly diminished the binding of the 3H-meta-PAL to the α 1-
subunit. In this case there could be detected an equivalent
binding of the 3H-meta-PAL both to the α 1- and the β 1-
subunit. It is described that ODQ inhibits sGC activity by
oxidation of the heme moiety from Fe2+ to Fe3+ or by
competition with the NO binding site [37,38]. Therefore
we propose that after interaction with ODQ the native
heme environment of the sGC is changed (e.g. by oxida-
tion), destroying the binding site for direct and NO-inde-
pendent sGC stimulators and therefore 3H-meta-PAL
unspecifically binds to both subunits of the sGC. The
slightly stronger labeling of the beta subunit would result
in this context from the possible higher available concen-
tration of free meta-PAL. This explanation is underlined
by the observation, that the heme-depleted enzyme is in-
sensitive towards stimulation by meta-PAL and other di-
rect and NO-independent sGC stimulators like BAY 41-
2272 or YC-1 [13,22]. Recently, Martin et al. [46] showed
that the stimulation of sGC by the new type of sGC stim-
ulators like YC-1 has both heme-dependent and heme-in-
dependent components. The stimulation of sGC by YC-1
is not completely blocked by ODQ, in particular in higher
concentrations of sGC stimulators. They conclude, that
the binding of ODQ and YC-1 are not mutually exclusive
processes and that their binding sites do not overlap.
These data corroborate our findings.
In addition, the 3H-meta-PAL labeled sGC was fragment-
ed by CNBr digest to identify the binding site of the 3H-
PAL at the α 1- s u b u n i t  m o r e  c l o s e l y .  I n  t h i s  s t u d y ,  t h e
chemical digest of the labeled sGC shows five highly la-
beled protein fragments on the Photo-Imaging-Plate of
the gradient gel in the molecular range between 6.2 and
Figure 4
Autoradiogram of 3H-meta-PAL (2, 20 and 200 µCi) labeled
sGC (12.5 and 25 µg) in the presence and absence of meta-
PAL (100 µM) after separation in both subunits by SDS-
PAGE.
Figure 5
Autoradiogram of 3H-meta-PAL labeled sGC after separation
by SDS-PAGE. Lane1: 12.5 µg sGC with 3H-meta-PAL with-
out irradiation; Lane 2: 12.5 µg sGC with 3H-meta-PAL after
irradiation; Lane 3: as 2 but in the presence of 100 µM unla-
beled meta-PAL; Lane 4: as 2 but in the presence of 10 µM
unlabeled meta-PAL; Lane 5: as 2 but in the presence of 100
µM ODQ; Lane 6: as 2 but in the presence of 100 µM YC-1.BMC Pharmacology 2001, 1 http://www.biomedcentral.com/1471-2210/1/13
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51.8 kDa and three highly labeled bands in the Photo-Im-
aging-Plate of the TRIS-Tricine-gel in the molecular range
between 6.2 and 14.7 kDa. These bands were identified
and excised from the Coomassie-blue stained blot and se-
quencing of these bands showed, that they contain differ-
ent fragments of both the α 1- as the β 1-subunit. Because
the 3H-meta-PAL binds specifically to the α 1-subunit of
the sGC and thereby all identified β 1-sequences could be
discarded, the overview of the determined α 1-sequences
shows, that the 3H-meta-PAL binds specifically to the
CNBr VIII fragment, consisting of the amino acids 236–
290 of the α 1-subunit. To more closely identify the bind-
ing site of the 3H-meta-PAL, the single PTH-cycles from
the sequencing of the CNBr VIII fragment were collected
and the cysteines 238 and 243 of the α 1-subunit were de-
tected as binding sites of 3H-meta-PAL.
As shown in Fig. 9, these cysteines are conserved between
the amino acid sequences of rat and human sGC [39,40]
and this region could play an important role in regulation
of sGC activity by this type of sGC. However, the putative
target of bovine sGC differs from rat and human by the
substitution of an arginine at position 238 instead of
cysteine. As shown in previous studies with YC-1 [11] and
verified in this study using crude bovine lung derived sGC
extracts, we know that cysteine 238 is not essential for the
stimulation of sGC by neither YC-1, nor BAY 41-2272, nor the PAL compound. However, is must be considered that
the potencies of BAY 41-2272 on human, rat and bovine
sGC could be different. For such comparison, the highly
purified guanylate cyclases from these three species are
needed. The mechanism of sGC stimulation is rather
more complicated than simple interaction with one or
two amino acids since the heme moiety bound to the His-
105 of the β 1-subunit is essential for activating the en-
zyme by YC-1, BAY 41-2272 and the PAL compound.
There is a distance of 9 Å between the photolabile azido
group and the pharmacophore of the compound. For this
reason a covalent binding of the 3H-PAL to reactive
cysteines slightly outside the binding pocket would not be
surprising. Nevertheless, we assumed that Cys-238 and
Cys-243 are in the direct region of access of 3H-PAL be-
cause no other labeled amino acids have been detected
and a diffusion over a wide distance can be excluded.
Recent studies with YC-1 implify that YC-1 binds to an al-
losteric site on sGC and thereby increases the maximal cat-
alytic rate and sensitises the enzyme towards its gaseous
activators NO and CO [11,13]. Studies about the kinetics
and equilibra of sGC in the presence of YC-1 led to a
mechanistic model, which attributes a crucial role to the
proximal bond that connects the heme iron to the histi-
dine 105 of the β 1-subunit of sGC [41,42], but also re-
quires protein control of the distal environment [43].
Firstly a small shift in the soret absorption feature of the
sGC by YC-1 is observed. It is discussed, that this small
Figure 6
Coomassie-blue stained Western Blot and autoradiogram of
photoaffinity labeled sGC fragments after CNBr digest and
SDS-PAGE on a 10–20% gradient gel (6 h exposition on
Imaging-Plate). Shown are a 14C-labeled rainbow molecular
weightmarker (14C-M), further molecular weightmarker,
photoaffinity labeled sGC (200 µg) after CNBr digest (sGC
CNBr) and for control undigested sGC (sGC; 5 µg). The
arrows show the molecular weightmarkers with their molec-
ular weights (kDa) or the 3H-meta-PAL labeled sGC frag-
ments (BrCN I-V) with their molecular weights, as calculated
after sequencing.
Figure 7
Coomassie-blue stained Western Blot and autoradiogram of
photoaffinity labeled sGC fragments after CNBr digest, SDS-
PAGE on a TRIS-Tricin-gel (16.5%) (48 h exposition on Imag-
ing-Plate screened by a folio of contamination monitors).
Shown are a 14C-labeled rainbow molecular weightmarker
(14C-M), further molecular weightmarkers, and photoaffinity
labeled sGC (200 µg) after CNBr digest (sGC CNBr). The
arrows show the molecular weightmarkers with their molec-
ular weights (kDa) or the 3H-meta-PAL labeled sGC frag-
ments (CNBr VI-VIII) with their molecular weights, as
calculated after sequencing.BMC Pharmacology 2001, 1 http://www.biomedcentral.com/1471-2210/1/13
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shift could be evoked by the replacement of the His-105
as the proximal heme ligand by another base, either an-
other amino acid side chain or even YC-1 itself [43].
In contrast to [21] who postulated the YC-1 binding site
in analogy to the forskolin binding site in the adenylate
cyclase within the catalytic region of the α 1- subunit of the
sGC in the region of cysteine 596, we showed that the new
generated photoaffinitylabel for direct and NO-independ-
ent sGC stimulators binds to the cysteines 238 and 243 in
the N-terminus of the α 1-subunit of the sGC and thereby
in the near of the heme binding region. Hobbs [44] pos-
tulated an intramolecular sixth ligand of the heme, which
oscillates on and off the sixth coordinate, thereby confer-
ring some sort of ligand specificity (i.e. NO and CO). The
binding of direct sGC stimulators to this site could block
this intramolecular binding site and thereby simplify the
binding of NO and CO to the enzyme. This model is con-
comitant with the sensitising of the enzyme towards NO
by this class of stimulators. Very recently our findings have
been supported [45] showing the important role of an ad-
ditional heme binding domain for sGC activation by the
NO-independent sGC stimulator YC-1. This domain is in
the α -subunit in vicinity of the PAL labeled region.
Conclusion
In summary, using photoaffinity labelling, we identified
the region of the cysteines 238 and 243 in the α 1 subunit
of sGC as the target for NO-dependent sGC stimulators.
However, the relevance of the identified region as a regu-
latory unit remains to be confirmed by mutational analy-
sis and co-crystallization studies.
Materials and Methods
Synthesis of YC-1 and the photoaffinity labels (PALs)
YC-1 ((3-(5-hydroxymethyl-2 furyl)-1-benzylindazole)
was synthesized as described [23] and was used as a 10
mM stock solution in DMSO. Three PAL candidates (BAY
50-6038, BAY 50-8364 and BAY 51-9491) were synthe-
tized from the common intermediate BAY 41-2272
[24,25] (Fig. 1). The azide derivatives were obtained by
deprotonation of the BAY 41-2272 primary amine with
sodium hydride followed by reaction with the corre-
sponding azide benzoyl chloride. The ortho- and para-azi-
dobenzoyl chlorides were synthesized by reaction of the
corresponding ortho- and para-azidobenzoic acid with
thionyl chloride. In order to obtain the meta-azido deriv-
ative, the benzoyl chloride was synthesized in situ by reac-
tion of the corresponding azidobenzoic acid [26] with 1-
chloro-N,N-2-trimethylpropenylamine [27] (Fig. 1). The
synthesis of the corresponding [3H]-BAY 51-9491 was ac-
complished as depicted in Fig. 2. Cyclization of the ami-
dine with ethyl cyano(cyclopropyl)acetate [28] afforded
the 6-amino-4-hydroxypyrimidine derivative, which was
converted to the bromo precursor by reaction with phos-
phoroxide tribromide. Br/3H exchange followed by for-
mation of the amide bond as detailed above yielded the
[3H]- BAY 51-9491.
Purification of soluble guanylate cyclase (sGC) and deter-
mination of sGC activity
sGC was highly purified from a baculovirus / Sf9 expres-
sion system and enzyme activity was measured by forma-
tion of [32P]-cGMP from [α -32P]-GTP modified according
to Gerzer [29] in the presence of Mg2+ as the divalent met-
al cation as described [11]. Incubations were performed in
the presence and absence of 1 mM DTT. All measurements
were performed in duplicate and were repeated three
times unless otherwise indicated. The specific activity of
sGC was calculated as nmol cGMP formed per mg protein
Figure 8
Course of the counted radioactivity of the single PTH-cycles
of the sequencing of the CNBr VIII band. Presented are the
measured dpm (decompositions per min, counting time 2 h).
The pointed line represents the potential regression of the
unspecific bound radioactivity, which is washed of the mem-
brane during the first cycles ("wash out").
Figure 9
Sequence alignment of 3 α 1 subunits (human, rat, bovine) and
2 α 2 subunits (human, rat). Invariant amino acids are shown
in red on yelow background. Amino acids building the con-
sensus are shown in black on blue background and amino
acids similar to the consensus are shown in black on red
background. The two labeled cysteines are marked with
arrows.BMC Pharmacology 2001, 1 http://www.biomedcentral.com/1471-2210/1/13
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per min incubation time. For characterisation of the dif-
ferent sGC stimulators the specific activity of sGC was ex-
pressed as x-fold stimulation vs. specific basal activity. The
highest DMSO concentration in the test was 1% (v/v) and
did not elicit any effect per se on cGMP production.
Spectroscopic studies
UV/Vis spectra were recorded from 300 to 600 nm on a
DU 640 spectrophotometer (Beckman, Munich, Germa-
ny). NO was introduced via an aqueous solution of DEA/
NO. A 100 mM stock solution of meta-PAL in DMSO was
prepared and added in a final concentration of 10 µM, re-
sulting in a final DMSO concentration of 0.1% (v/v),
which does not alter the properties of the enzyme.
Evaluation of CH- and NH-insertion qualities of the meta-
PAL
Meta-PAL (BAY 51-9491) was dissolved in diethylamine,
dipropylamine, piperidine, toluene, or ethylbenzole in a
concentration of 1 mg/ml and degassed by three thaw-
freeze-cycles. 1 ml of each solution was given in a well of
a 24 well PET plate (Wallac, Turku, Finland) and irradiat-
ed with a UV hand lamp at 254 or 365 nm in a distance of
3 cm for 2 h (254 nm: N8K UV 254 nm hand lamp, Ben-
da, Wiesloch, Germany; 365 nm: Universal UV lamp, CA-
MAG, Berlin, Germany). Solutions were evaporated in a
Speed Vac (Bachofer, Reutlingen, Germany) and qualita-
tively and quantitatively analysed by LC / MS (column:
symmetry C18, 2.1 ×  150 mm; eluent: A: acetonitrile, B:
0.6 g HCl (30%) in 1 l MilliQ water; gradient: time 0: 10%
A and 90% B flow: 0.6 ml/min, time 4 min: 90% A and
10% B flow: 0.6 ml/min, time 9.5 min: 10% A and 90% B
flow: 0.8 ml/min; at 50°C). Resulting products were con-
sidered as NH- or CH-insertion products if their molecu-
lar weights correspond to the calculated weight of the
insertion product and were given as % peak area of total
peak area. To evaluate the irradiation time required for N2
degradation, meta-PAL (1 mg/ml) was dissolved in PAL
buffer (final 50 mM TEA/HCl, 0.1 mM EGTA, 1 mM
cGMP, 3 mM MgCl2, 200 µM GTP, pH 7.4) in the absence
and presence of 0.3 mg/ml glucose oxidase as model pro-
tein and irradiated as described at 254 nm. Every minute
an aliquot was removed and fragmented compounds were
separated from meta-PAL by thin layer chromatography
(stationary phase: silicagel 60 layered glass plate 5 ×  10 cm
(Merck, Darmstadt, Germany); mobile phase: acetoace-
tate).
Labeling of purified sGC
12.5 or 25 µg sGC (purity about 91%) were dissolved in
PAL buffer (final 50 mM TEA/HCl, 0.1 mM EGTA, 1 mM
cGMP, 3 mM MgCl2, 200 µM GTP, pH 7.4) and incubated
with 200, 20 or 2 µCi 3H-meta-PAL (specific activity: 7.9
Ci/mmol ≅  0.29 MBq/nmol) in the presence or absence of
100 µM meta-PAL in a volume of 80 or 100 µl in a 24 well
PET plate (5 min, 37°C). Samples were irradiated at 254
nm (distance 3 cm, 20°C, 15 min) and the reaction was
stopped by adding 20 or 25 µl SDS-containing stop solu-
tion (312.5 mM TRIS/HCl / 10% (w/v) SDS / 50% (v/v)
glycerine / 250 mM DDT / 0.025% (w/v) bromphenolb-
lue, pH 6.8) and heating (5 min at 80°C).
In a further study 12.5 µg sGC were incubated with 20 µCi
3H-meta-PAL in the presence and absence of the different
sGC modulators as indicated, irradiated and stopped as
described. For controls 12.5 µg sGC were incubated with
20 µCi 3H-meta-PAL without irradiation and 12.5 µg glu-
cose oxidase were irradiated as described in the presence
of 20 µCi 3H-meta-PAL. Separation was performed on a
7,5% SDS-PAGE (PROTEAN II cell, Bio-Rad, München,
Germany) using a modified Laemmli method [30]. After
electrophoresis, proteins were fixed for 20 min in metha-
nol/acetic acid/ MilliQ water (30/10/60), dried and ex-
posed to BAS-TR 20/25 Imaging-Plates (Ray Test,
Straubenhardt, Germany) for 15 days as described [31].
After exposure, the imaging plates were scanned (BAS
5000 Scanner, Ray Test, Straubenhardt, Germany). Evalu-
ation was performed by visual classification of radio-
graphic intensities, displayed by use of pseudo-colours,
starting with blue for lowest detectable concentrations up
to red for highest concentrations as shown in each figure
by a gradation bar.
Figure 10
Stimulation of the crude sGC preparation from bovine lung
by BAY 41-2272 in the absence and presence of DEA/NO
(10  µM). The specific activity of sGC preparation is
expressed as x-fold stimulation vs. basal activity (basal activity
in the presence of Mg2+: 152 nmol/mg/min). The data pre-
sented represent means ± SEM, from 4 independent experi-
ments performed in duplicate.
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CNBr fragmentation of labeled sGC
200 µg sGC were labeled as described with 1600 µCi 3H-
meta-PAL, and the reaction was stopped by the addition
of final 10% TCA. The labeled protein was precipitated
(4°C, 30 min), centrifuged (14,000 rpm, 30 min; Centri-
fuge 5415C, Eppendorf, Hamburg, Germany) and washed
two times with ice cold ethanol:ether (1:1). The protein
pellet was dissolved in formic acid (70%) and reacted
with a few crystals of CNBr in the dark (24 h, 20°C) under
oxygen-free nitrogen. After evaporation in a Speed Vac
(Bachofer, Reutlingen, Germany) for three times after the
addition of 1 ml MilliQ water, the pellet was dissolved in
100 µl sample buffer (62.5 mM TRIS/HCl / 2% (w/v) SDS
/ 10% (v/v) glycerine / 50 mM DDT / 0.0025% (w/v)
bromphenolblue, pH 6.8), heated (5 min, 80°C) and the
protein fragments were separated on a 10–20% gradient
SDS-PAGE or a 16.5% TRIS-Tricine-gel [32], respectively.
The digested protein fragments were transferred to a PVDF
membrane (Trans-Blot® Electrophoretic Transfer Cell,
Bio-Rad, München, Germany) [33], stained with 0.025%
(w/v) Coomassie-blue-R / 40% (v/v) MeOH and
destained in 50% (v/v) MeOH. Dried membranes were
exposed to BAS-TR 20/25 Imaging-Plates (Ray Test,
Straubenhardt, Germany) for 6 h (10–20% gradient gel
blot) without or for 48 h with a screen of metal folio for
contamination monitors (0.9 mg/cm2Steiner, Erndte-
brück-Schameder, Germany) (16.5% TRIS-Tricine-gel
blot) [31]. After exposure, the Imaging Plates were
scanned and evaluation was performed as described
above.
N-terminal sequence analysis
N-terminal sequence analyses were performed using the
gas-liquid-solid-phase protein sequencer Procise™ from
Applied Biosystems (Forster City, CA., U.S.A.). The se-
quencer program for blot sequencing was used according
to the manufacturer s standard protocol (User's manual
set Procise™, 1994; Applied Biosystems, Forster City,
USA). The detection of PTH-amino acids was performed
on-line using an RP-18-PTH-column (220 mm ×  2 mm, 5
µm-material) from Applied Biosytems. The PTH-amino
acids were identified and quantified by a 50 pmol PTH-
standard. The data were collected and integrated using the
sequencer data system (Protein sequencing protocols; ed.
Bryan John Smith; Humana Press INC.; Totowa, New Jer-
sey).
Sequence analysis
PVDF-membrane pieces were washed twice with 100 µl
50% (v/v) MeOH before sequencing. The cyanogen bro-
mide fragment CNBrVIII was sequenced over 60 cycles us-
ing the sequencer program for blot sequencing. The single
PTH-amino acids were collected (fraction collector Super-
rac 2211, Pharmacia) lyophilised, dissolved in acetonitril
and MeOH and transferred to Combust-Cones, filled with
two Combust-Pads (Packard, Illinois, USA). The radioac-
tivity of each fraction was determined after combustion
(Oxidizer model 307, Oximate 80, Packard, Illinois, USA)
and dissolution of resulting gases in 15 ml scintillator
(Monophase Scintillator, Packard) with a counting time
of 2 h in a liquid scintillation counter (LS-6500, Beck-
mann, München, Germany).
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